Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06391723

Clinical, Cognitive and Neural Effects of Potentiation of ECT by rTMS in Treatment-Resistant Depression

Electroconvulsive therapy (ECT) is one of the most effective treatments for treatment-resistant depression (TRD). However, due to response delay and cognitive impairment, ECT remains an imperfect treatment. In this multicenter, randomized, double-blind, sham-controlled study, our objective is to assess the priming effect of rTMS sessions before ECT on clinical, cognitive and neural response in patients with TRD.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

80 patients with TRD will be assigned to active or sham rTMS before ECT treatment. Five sessions of active/sham rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session) before ECT (which was active for all patients) started. Then, from the sixth ECT session, an rTMS session will occur the day before each ECT session. Clinical assessment, cognitive assessment and brain imaging (structural MRI, resting state functional MRI, MR spectroscopy) will take place before and after 10 ECT sessions. Clinical, cognitive and neural changes will be compared between both groups after 10 ECT sessions.

The primary outcome will be the response rate after 10 ECT, i.e. the percentage of patients who achieved a reduction of 50% or more from their initial Hamilton Depression Scale score (HAMD-21 items).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria
  • HAMD score ≥15
  • In case of unipolar disorder: no remission after at least two different antidepressants prescribed at a dose and duration sufficient for the current episode
  • In the case of bipolar disorder: no remission despite lithium at an adequate plasma level combined with lamotrigine or quetiapine monotherapy at full dose
  • No change of antidepressant or mood stabilizer treatment for at least 15 days
  • To be rTMS-naive
  • Without benzodiazepine or antiepileptic treatment for at least 15 days
  • To understand spoken and written French
  • Having given their informed, written consent

Exclusion criteria

  • Contraindication to Electroconvulsive therapy (ECT), repeated Transcranial Magnetic Stimulation (rTMS), Magnetic Resonance Imaging (MRI), anesthesia
  • Patients who have received ECT in the last 6 months
  • Patients suffering from poorly stabilized epilepsy, serious neurological or systemic disorders
  • Patients with a serious substance use disorder (other than nicotine or caffeine) according to DSM-5 criteria
  • Patients suffering from severe hearing problems
  • Subjects already treated with an electrical or magnetic stimulation technique
  • Women who do not have adequate contraception, pregnant or breastfeeding women
  • Being deprived of liberty by an administrative or judicial decision
  • Patients participating or having participated in an interventional clinical trial within 30 days before the inclusion visit

Treatment and study plan

Active rTMS

Device

rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)

sham rTMS

Device

Sham rTMS will be administered over the left dorsolateral prefrontal cortex

Primary outcomes

  1. Response rate after 10 ECT

    Time frame: Day 0 and Day 40

    the percentage of patients who achieved a reduction of 50% or more from their initial Hamilton Depression Scale score (HAMD-21 items)

Secondary outcomes

  1. The relative improvement of depressive symptoms throughout the study (assessed by a clinician)

    Time frame: Day 0, Day 4, Day 19, Day 26, Day 40

    the relative variation of HAMD-21

  2. The relative improvement of depressive symptoms throughout the study (self-reported)

    Time frame: Day 0, Day 4, Day 19, Day 26, Day 40

    Quick Inventory of Depressive Symptomatology

  3. Adverse effects

    Time frame: Day 4, Day 19, Day 26, Day 40

    Assessment of adverse effects with the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale adapted to rTMS (adapted UKU)

  4. Subjective assessment of memory

    Time frame: Day 4, Day 19, Day 26, Day 40

    Scores and variations in memory assessed with the Squire Subjective Memory Questionnaire (SSMQ)

  5. Subjective assessment of cognitive functioning

    Time frame: Day 4, Day 19, Day 26, Day 40

    Scores and variations in cognitive functioning assessed with the Cognitive Failures Questionnaire (CFQ)

  6. Global cognitive functioning (objective)

    Time frame: Day 0 and Day 40

    Scores and variations assessed with the Mini Mental Status Examination

  7. Verbal memory performances (objective)

    Time frame: Day 0 and Day 40

    Scores and variations assessed with the RL/RI-16 test

  8. Attention (objective)

    Time frame: Day 0 and Day 40

    Scores and variations assessed the D2 test of attention

  9. Visuospatial and constructional ability (objective)

    Time frame: Day 0 and Day 40

    Scores and variations assessed with the Rey-Osterrieth complex figure test

  10. Autobiographical memory (objective)

    Time frame: Day 0 and Day 40

    Scores and variations assessed with the autobiographical memory test (TEMPau)

  11. Seizure threshold

    Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37

    Seizure threshold during ECT

  12. Seizure duration

    Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37

    Seizure duration during ECT

  13. Postictal Suppression

    Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37

    Postictal Suppression during ECT

  14. Dose of medication

    Time frame: Day 5, Day 9, Day 11, Day 16, Day 18, Day 23, Day 25, Day 30, Day 32, Day 37

    Dose of medication during ECT

  15. Changes in regional gray matter density

    Time frame: Day 0 and Day 40

    Changes in regional gray matter density measured with 3D MRI

  16. Changes in cortical thickness

    Time frame: Day 0 and Day 40

    Changes in cortical thickness measured with 3D MRI

  17. Brain activity and biochemical changes

    Time frame: Day 0 and Day 40

    Changes measured with Resting state functional MRI and spectroscopy MRI

Study contacts

Contact information is provided by the study sponsor or research team.

Maud Rotharmel

CONTACT

[email protected]

+33232956825

Virginie Moulier

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Centre Hospitalier du Rouvray

Other Gov

Collaborators

  • Centre Hospitalier Sainte Anne, Paris
  • University Hospital, Rouen

Registry information

Official study title

Clinical, Cognitive and Neural Effect of Potentiation of Electroconvulsive Therapy (ECT) by Repetitive Transcranial Magnetic Stimulation (rTMS) at 10 ECT in Patients With Characterized Pharmacoresistant Depressive Episode

Acronym: STIMAGNECT2

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 30, 2024
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.